France’s healthcare system is to benefit from €7bn worth of investment, which is designed to drive innovation in the sector.
Speaking at the end of June, French President Emmanuel Macron announced that public funding would be made available in the wake of the COVID-19 pandemic in the country.
Part of France’s Health Innovation Plan 2030, €2bn will be invested by the state-owned Banque Publique d'Investissement (BPI) in start-ups and small and medium-sized companies (SMEs) in the healthcare industry.
France will also invest €2bn in research for emerging and infectious diseases, biotherapies and digital health.
Following the COVID-19 pandemic, the plan will allocate almost €750 million for emerging infectious diseases and CBRN (nuclear, radiological, biological and chemical) threats.
Another €800m will be dedicated to biotherapies and the bioproduction of innovative therapies that represent 50% of the clinical trials currently underway.
These technologies enable the development of so-called personalised medicine by providing therapeutic solutions in oncology, immunology, virology and for rare diseases, for example.
President Macron wants to make France the leading European country in healthcare innovation by 2030. He has committed to lift administrative hurdles to speed up organisational changes in the healthcare system.
*Image by Parentingupstream from Pixabay